| Drug Name | GPCR-targeted Project 017 |
| Description |
Frizzled 5 (FZD5) is highly expressed in ovarian cancer cells, associated with poor prognosis, such as its ligand WNT5a. A humanized monoclonal antibody (mAb) targeting FZD5 is being developed for the treatment of ovarian cancer. |
| Target | Frizzled 5 (FZD5) |
| Drug Modality | Monoclonal antibody |
| Indication | Ovarian cancer |
| Product Category | Biologic |
| Mechanism of Action | Wnt signaling pathway stimulants |
| Status | Discovery |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |